SNY News & Analysis
2 articles
Market Mood
Sanofi SA (SNY) Appoints New R&D Head Amid 5% Dividend Yield
Sanofi SA (NASDAQ: SNY) announced the appointment of Paulo Fontoura as Executive Vice President and Global Head of Research & Development effective September 1. Fontoura will oversee the company's end-to-end innovation engine across multiple therapeutic areas, succeeding Dr. Houman Ashrafian. The appointment is significant as Sanofi progresses in its R&D transformation and aims to accelerate the development of new medicines. Additionally, MacroGenics confirmed it will receive $24.5 million from Sanofi due to regulatory milestone payments related to the FDA's accelerated approval of TZIELD.
Read More: Sanofi SA (SNY) Appoints New R&D Head Amid 5% Dividend Yield
Sanofi ADR (SNY) Form 6K Filed on 12 June 2023
Sanofi (SNY) filed a Form 6K on June 12, 2023, which is an official document submitted to the U.S. Securities and Exchange Commission. This filing typically contains important updates concerning the company's financial position or operational changes. Such filings are essential for investors as they provide transparency and insight into the company's activities and can influence trading decisions. The market often reacts to these filings based on the information disclosed within them.
Read More: Sanofi ADR (SNY) Form 6K Filed on 12 June 2023